Arrowhead Reports Topline Results From Pivotal Phase 3 PALISADE Study Of Investigational Plozasiran; Says Study Successfully Met Primary Endpoint Of Lowering Triglycerides And Met All Key Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Arrowhead Pharmaceuticals reported positive topline results from its Phase 3 PALISADE study of investigational Plozasiran, meeting both primary and key secondary endpoints. The company plans to present this data at its June 25, 2024, Cardiometabolic event.
June 03, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arrowhead Pharmaceuticals announced successful Phase 3 results for Plozasiran, meeting primary and secondary endpoints. This is a significant milestone for the company, likely to positively impact its stock price in the short term.
The successful Phase 3 results for Plozasiran are a critical milestone for Arrowhead Pharmaceuticals, indicating potential future revenue from this treatment. The upcoming presentation of this data is likely to generate further investor interest, positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100